Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419439 | 0.82 | MCL1 (0.66) | PTGDR2MEN1KMT2A | |
| SCHEMBL6419441 | 0.82 | MCL1 (0.66) | PTGDR2MEN1KMT2A | |
| SCHEMBL6419445 | 0.82 | MCL1 (0.66) | PTGDR2MEN1KMT2A | |
| SCHEMBL6420229 | 0.80 | PTGDR2 (0.70) | PTGDR2MEN1KMT2A | |
| SCHEMBL6420089 | 0.79 | PTGDR2 (0.48) | PTGDR2MEN1KMT2A | |
| SCHEMBL6418944 | 0.77 | MEN1 (0.64) | PTGDR2MEN1KMT2A | |
| SCHEMBL6420258 | 0.77 | MCL1 (0.56) | PTGDR2MEN1KMT2A | |
| SCHEMBL225450 | 0.77 | NOTUM (0.55) | PTGDR2MEN1KMT2A | |
| SCHEMBL223899 | 0.77 | NOTUM (0.55) | PTGDR2MEN1KMT2A | |
| SCHEMBL253608 | 0.77 | NOTUM (0.55) | PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | PTGDR2 1670/4885MEN1 580/4885KMT2A 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.